Publication at First Faculty of Medicine |
2015
Abstract
Elevated fasting blood glucose is associated with a significantly increased risk of cardiovascular complications, therefore its influence is very important way how to improve glycemic control and also potentially positively influence cardiovascular risk. The most effective therapeutic modality influencing fasting hyperglycemia is the use of long-acting insulin.
In this paper we focus on three innovations in the field of long-acting insulins - insulin glargine U300, degludek insulin degludek and pegylated insulin lispro. Previous results indicate that this new generation of long-acting insulin is characterized by more preferable pharmacokinetic properties that lead to reduced incidence of hypoglycemia and better patient comfort.